The invention discloses a drug for treatment and postoperative care of uterus myoma, and belongs to the field of traditional Chinese medicines. The effective constituents of the drug comprise the following raw materials in parts by weight: 70-90 parts of white atractylodes rhizome, 60-80 parts of angelica, 55-75 parts of codonopsis pilosula, 50-70 parts of fried schizonepeta spike, 45-60 parts ofcortex moutan, 40-55 parts of cassia twig, 35-50 parts of white paeony root, 30-45 parts of herba leonuri, 25-43 parts of ligusticum wallichii, 22-40 parts of peach kernel, 18-35 parts of rhizoma sparganii, 15-30 parts of raw rhubarb, 12-25 parts of curcuma zedoary, 8-20 parts of scutellaria baicalensis, 5-16 parts of poria cocos and 3-12 parts of radix cyathulae. According to the invention, the raw materials are reasonably mixed, the raw materials capable of promoting blood circulation to remove blood stasis, resolving hard lump, warming, activating meridian and tonifying vital energy and spleen are selected for pathogenic factors such as cold congealing stasis, spleen deficiency and damp obstruction, dried blood accumulation, uterus stasis and the like; the effects of finding a disease source by visiting and treating both symptoms and root causes are achieved by regulating the whole-body function and activating the immune system of a patient; and the drug has a very good treatment effect for intramural myoma, subserous myoma, submucous myoma and cervix myoma through clinic verification.